Can Sorafenib Cause Hypothyroidism?
Abstract
"Can Sorafenib Cause Hypothyroidism?." Journal of Chemotherapy, 19(3), pp. 352–353
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A number of kinase inhibitors, including imatinib and sunitinib, appear to influence thyroxine requirements through what is likely a class effect.
“A number of kinase inhibitors, including imatinib and sunitinib, appear to influence thyroxine requirements through what is likely a class effect [114–116].”
From Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report (2017) · cites this paper as [116]
Cites
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 402 · see citing works
Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Rini, B. I., Tamaskar, I., Shaheen, P., Salas, R. N., Garcia, J., Wood, L. S., Reddy, S. S. K., Dreicer, R., & Bukowski, R. M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk008 · Cited by 378 · see citing works
Escudier, B. J., Szczylik, C. A., Eisen, T. G., Stadler, W. M., Schwartz, B. E., Shan, M., & Bukowski, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4510 · Cited by 347 · see citing works
Imatinib induces hypothyroidism in patients receiving levothyroxine
DEGROOT, J., ZONNENBERG, B., PLUKKER, J., VANDERGRAAF, W., & LINKS, T. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.010 · Cited by 159 · see citing works
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine
de Groot, J. W. B., Links, T. P., & van der Graaf, W. T. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl112 · Cited by 51 · see citing works
Recent Advances in the Research and Development of RAF Kinase Inhibitors
Smith, R. A., Dumas, J., Adnane, L., & Wilhelm, S. M. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812077 · Cited by 48 · see citing works
Sunitinib-related thyroid dysfunction: A single-center retrospective and prospective evaluation
Schoeffski, P., Wolter, P., Himpe, U., Dychter, S. S., Baum, C. M., Prenen, H., Wildiers, H. P. M. W., Bex, M., & Dumez, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3092 · Cited by 33 · see citing works
Conjugated Estrogen Therapy and Tests of Thyroid Function
Heath, H., LEE, R. B., DIMOND, R. C., & WARTOFSKY, L. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-3-351 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470 · see citing works
Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
Centanni, M., Benvenga, S., & Sachmechi, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0706-y · Cited by 113 · see citing works
Morris, J. C. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03536.x · Cited by 59 · see citing works
Self-citationCurrent awareness: Pharmacoepidemiology and drug safety
John Wiley & Sons, L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1485
- Authors
- Robinson, S. I., Hobday, T. J., Sathananthan, A., Morris, J. C., & Mcwilliams, R. R.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Hobday, T.J.
- Venue
- Journal of Chemotherapy
- Publisher
- Informa UK Limited
- Published
- 2007-06
- Volume
- 19
- Issue
- 3
- Pages
- 352-353
- ISSN
- 1120-009X (ISSN-L)
- 1973-9478
- OpenAlex
- W1986979658
- Cited by
- 4
- References
- 8
- Citations by year
- 2017: 1
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Keywords
- sorafenib, hypothyroidism, drug-induced thyroid dysfunction, adverse drug reactions, tyrosine kinase inhibitors
- MeSH terms
- Sorafenib, Antineoplastic Agents, Benzenesulfonates, Female, Humans, Hypothyroidism, Liver Neoplasms, Niacinamide, Pancreatic Neoplasms, Phenylurea Compounds, Pyridines, Carcinoma, Islet Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
